Active Clinical Trials

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

By April 24, 2017 No Comments



Estimated Enrollment: 125

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: IFCT-1501

Study First Received: March 9, 2016

Last Updated: October 24, 2016

Estimated Primary Completion Date: May 2017


Primary Outcome Measures:

Disease Control rate assessed by CT scan|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Progression-Free Survival|Overall Survival|Quality of Life|prognosis impact of blood biomarkers (exploratory studies)

Sponsors and Collaborators:

Intergroupe Francophone de Cancerologie Thoracique

Website Link:

Leave a Reply

Call Now ButtonCall Now